Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Endovia Health Sciences says the federal government’s affirmative support for moving/recognizing cannabinoids under Schedule III is a meaningful policy evolution for the U.S. cannabinoid market. The headline implication is reduced regulatory friction versus prior scheduling, which could be supportive for the company’s outlook, though the excerpt provides no financial magnitude.